Recursion Pharmaceuticals, Inc. (RXRX) Tops Q4 EPS by 4c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q4 EPS of ($0.42), $0.04 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $10.89 million versus the consensus estimate of $19.9 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• Serve Robotics names Andreas Lieber to its board of directors
• Hertz cuts guidance, announces notes and stock offerings, shares sink